Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce …

immunosuppression
flow cytometry
filgrastim
apheresis
cyclophosphamide
  • 0 views
  • 25 Jan, 2021
  • 1 location
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

flow cytometry
leukemia
lymphocytic leukemia
monoclonal antibodies
  • 0 views
  • 06 Sep, 2021
  • 1 location
CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.

  • 0 views
  • 01 Oct, 2021
  • 1 location
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical …

pleural effusion
tyrosine
tyrosine kinase inhibitor
cyclophosphamide
platelet count
  • 9 views
  • 13 May, 2022
  • 10 locations
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia. Patients will be

  • 0 views
  • 06 Sep, 2021
  • 1 location
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

measurable disease
monoclonal antibodies
tyrosine
platelet count
venetoclax
  • 0 views
  • 24 Mar, 2022
  • 6 locations
FT819 in Subjects With B-cell Malignancies

Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

flow cytometry
lymphocytic leukemia
b-cell acute lymphoblastic leukemia
tyrosine
cancer chemotherapy
  • 0 views
  • 15 Dec, 2021
  • 5 locations
CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL

This is a single arm, open-label, multi-center prospective study to determine the safety and efficacy of CD19 UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B cell acute

leukemia
cancer chemotherapy
lymphocytic leukemia
lymphoma
  • 0 views
  • 12 May, 2022
  • 1 location
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL

To evaluate the safety and efficacy of CD19/CD22 Bispecific CAR-T for the treatment of MRD-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy

lymphoid leukemia
consolidation therapy
fludarabine
oximetry
cyclophosphamide
  • 9 views
  • 08 Jun, 2022
  • 1 location
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

This is a single-cohort pilot study; patients will receive 131-I apamistamab 75 mCi prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab.

  • 0 views
  • 15 Jun, 2021
  • 1 location